



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Boulanger, D. et al.

Serial No.: 10/523,836

Art Unit: Not yet assigned

Filed : February 7, 2005

Examiner: Not yet assigned

For : **USE OF NF-KAPPA B INHIBITORS FOR THE TREATMENT OF MASTITIS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

11-15-05

(Date of Deposit)

Ellen Ciambone Coletti

(Name of applicant, assignee, or Registered Representative)



(Signature)

11-15-05

(Date of Signature)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Sequence Disclosures of September 15, 2005, please amend the above-identified application as follows:

Amendments to the Specification are provided as new written Sequence Listing section. Applicant submits that the amendment to the specification does not include new matter. The amendment adds a written Sequence Listing to comply with 37 CFR §1.821-825, as requested in the Notice to Comply of September 15, 2005, corresponding to the sequences disclosed in the specification as filed. Applicants believe that the sequences provided in the Sequence Listing filed herewith correspond to those as presented in the specification.

**REMARKS**

In response to the Notice to Comply with Requirements for Patent Applications Containing Sequence Disclosures, Applicants submit herewith a Sequence Listing as requested to comply with 37 CFR §1.821-825 and incorporate the Sequence Listing as originally presented on page 6 of the specification as originally filed. Since the existing